Harrow Gains After Reaffirming FY25 Revenue Guidance

Dow Jones02-02

By Elias Schisgall

Shares of Harrow rose after the company reaffirmed its full-year guidance for revenue between $270 million and $280 million.

Shares were trading up 6.9% to $43.76 Monday morning The stock has gained 47% in the past year.

The ophthalmic disease management company said Monday that its confidence in the outlook was based on execution across its programs.

Harrow said it was looking to double the Veyve sales force to 100 by Memorial Day and double the surgical-based sales force for Triesence. The company is also looking to expand Iheezo into the office-based setting, which it said is expected to accelerate demand.

The company said Monday that Patrick Sullivan, who joined Harrow as head of commercial in August, was promoted to chief commercial officer.

Following the September acquisition of Melt Pharmaceuticals, Harrow said that it remains on track to file a New Drug Application for Melt-300 in the first half of 2027.

Harrow also said that its ImprimisRx business was voluntarily leaving the California market after paying a $157,000 fine to the California Board of Pharmacy, citing the state's "increasingly unpredictable, costly, and punitive regulatory environment." It said the exit from California was not financially material to Harrow.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

February 02, 2026 10:07 ET (15:07 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608789858?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 23:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608789858","market":"us","top_or_hot":-1,"title":"Harrow Gains After Reaffirming FY25 Revenue Guidance","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Harrow rose after the company reaffirmed its full-year guidance for revenue between $270 million and $280 million. \n</p>\n<p>\n  Shares were trading up 6.9% to $43.76 Monday morning  The stock has gained 47% in the past year. \n</p>\n<p>\n  The ophthalmic disease management company said Monday that its confidence in the outlook was based on execution across its programs. \n</p>\n<p>\n  Harrow said it was looking to double the Veyve sales force to 100 by Memorial Day and double the surgical-based sales force for Triesence. The company is also looking to expand Iheezo into the office-based setting, which it said is expected to accelerate demand. \n</p>\n<p>\n  The company said Monday that Patrick Sullivan, who joined Harrow as head of commercial in August, was promoted to chief commercial officer. \n</p>\n<p>\n  Following the September acquisition of Melt Pharmaceuticals, Harrow said that it remains on track to file a New Drug Application for Melt-300 in the first half of 2027. \n</p>\n<p>\n  Harrow also said that its ImprimisRx business was voluntarily leaving the California market after paying a $157,000 fine to the California Board of Pharmacy, citing the state's \"increasingly unpredictable, costly, and punitive regulatory environment.\" It said the exit from California was not financially material to Harrow. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 02, 2026 10:07 ET (15:07 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harrow Gains After Reaffirming FY25 Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarrow Gains After Reaffirming FY25 Revenue Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-02 23:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Harrow rose after the company reaffirmed its full-year guidance for revenue between $270 million and $280 million. \n</p>\n<p>\n  Shares were trading up 6.9% to $43.76 Monday morning  The stock has gained 47% in the past year. \n</p>\n<p>\n  The ophthalmic disease management company said Monday that its confidence in the outlook was based on execution across its programs. \n</p>\n<p>\n  Harrow said it was looking to double the Veyve sales force to 100 by Memorial Day and double the surgical-based sales force for Triesence. The company is also looking to expand Iheezo into the office-based setting, which it said is expected to accelerate demand. \n</p>\n<p>\n  The company said Monday that Patrick Sullivan, who joined Harrow as head of commercial in August, was promoted to chief commercial officer. \n</p>\n<p>\n  Following the September acquisition of Melt Pharmaceuticals, Harrow said that it remains on track to file a New Drug Application for Melt-300 in the first half of 2027. \n</p>\n<p>\n  Harrow also said that its ImprimisRx business was voluntarily leaving the California market after paying a $157,000 fine to the California Board of Pharmacy, citing the state's \"increasingly unpredictable, costly, and punitive regulatory environment.\" It said the exit from California was not financially material to Harrow. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 02, 2026 10:07 ET (15:07 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HROW","symbol_name":"Harrow Health Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2608789858","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608789858","pubTimestamp":1770044820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Harrow rose after the company reaffirmed its full-year guidance for revenue between $270 million and $280 million.Shares were trading up 6.9% to $43.76 Monday morning  The stock has gained 47% in the past year.The ophthalmic disease management company said Monday that its confidence in the outlook was based on execution across its programs.Harrow said it was looking to double the Veyve sales force to 100 by Memorial Day and double the surgical-based sales force for Triesence. The company is also looking to expand Iheezo into the office-based setting, which it said is expected to accelerate demand.The company said Monday that Patrick Sullivan, who joined Harrow as head of commercial in August, was promoted to chief commercial officer.Following the September acquisition of Melt Pharmaceuticals, Harrow said that it remains on track to file a New Drug Application for Melt-300 in the first half of 2027.Harrow also said that its ImprimisRx business was voluntarily leaving the Calif","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HROW":"Harrow Health Inc","BK4557":"大麻股","BK4007":"制药"},"translate_title":"哈罗重申2025财年收入指引后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Harrow rose after the company reaffirmed its full-year guidance for revenue between $270 million and $280 million. \n\n\n  Shares were trading up 6.9% to $43.76 Monday morning  The stock has gained 47% in the past year. \n\n\n  The ophthalmic disease management company said Monday that its confidence in the outlook was based on execution across its programs. \n\n\n  Harrow said it was looking to double the Veyve sales force to 100 by Memorial Day and double the surgical-based sales force for Triesence. The company is also looking to expand Iheezo into the office-based setting, which it said is expected to accelerate demand. \n\n\n  The company said Monday that Patrick Sullivan, who joined Harrow as head of commercial in August, was promoted to chief commercial officer. \n\n\n  Following the September acquisition of Melt Pharmaceuticals, Harrow said that it remains on track to file a New Drug Application for Melt-300 in the first half of 2027. \n\n\n  Harrow also said that its ImprimisRx business was voluntarily leaving the California market after paying a $157,000 fine to the California Board of Pharmacy, citing the state's \"increasingly unpredictable, costly, and punitive regulatory environment.\" It said the exit from California was not financially material to Harrow. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 02, 2026 10:07 ET (15:07 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608789858","isCrawlerRequest":true}